2011 Sino US pharmaceutical industry summit held successfully

Source: Mr sang Guowei, vice chairman of the Standing Committee of the National People's Congress of China and academician of the Chinese Academy of engineering, attended the summit and delivered a speech at the 2011 Sino US pharmaceutical industry summit held in Beijing on October 18, 2011 At the meeting, the China Pharmaceutical Industry Research and Development Promotion Association and the pharmaceutical research and manufacturers of America (Pharma) jointly signed the joint statement on strengthening the protection of intellectual property rights, promoting the innovation and development of the pharmaceutical industry, and improving the level of public health Mr sang Guowei, vice chairman of the Standing Committee of the National People's Congress and academician of the Chinese Academy of engineering, attended the summit and delivered a speech "The Chinese government attaches great importance to the protection of intellectual property rights," he said Strengthening the protection of pharmaceutical intellectual property is not only an inevitable requirement to protect the legitimate rights and interests of innovators, but also an important legal measure to implement the national policy of supporting the creation of new drugs and encouraging innovation It is hoped that this summit will give full play to the role of two pharmaceutical professional groups as bridges and ties between China and the United States in the pharmaceutical industry, and contribute to promoting the intellectual property protection and innovation development of the global pharmaceutical industry and improving the level of human health protection " Chris wiebach, chairman of the board of directors of PhRMA, delivered a keynote speech Mr Christopher Viehbacher, chairman of the board of directors of PhRMA, said: "innovation is the key to ensure the development and clinical application of new drugs We are honored to cooperate with the China Council for the promotion of drugs on the important issue of intellectual property rights China's influence on the global biomedical industry is growing day by day I believe that the cooperation between the two sides will promote the development of more safe and effective drugs between China and the United States, and improve the health of patients around the world " In the declaration, both sides promised to improve the health of the two peoples by providing safe and effective new drugs to patients In addition, both sides believe that a sound intellectual property protection system is essential for the sustainable innovation of the biomedical industry Only through continuous innovation can we realize the commitment of both sides to patients In order to ensure the sustainable innovation of the pharmaceutical industry and promote the development of the industry, both parties propose to promote the relevant government departments of both sides to formulate and implement a series of supporting policies to protect various intellectual property rights in the pharmaceutical industry On the basis of the above consensus, the China Pharmaceutical Industry Research and Development Promotion Association and the American pharmaceutical research and development and manufacturers association signed the joint statement on strengthening the protection of intellectual property rights, promoting the innovation and development of the pharmaceutical industry, and improving the level of public health He said that he would establish closer cooperation, assist relevant government departments to establish and implement intellectual property protection systems, and create a policy environment for promoting the research and development of safe, effective and technology intensive new drugs In addition, the two sides promised to strengthen the protection of biomedical intellectual property rights of the two countries by promoting cooperation between all relevant parties, promoting the continuous improvement of the legal system This China US pharmaceutical industry summit is co sponsored by China International Chamber of Commerce, China Pharmaceutical Council, American Chamber of Commerce and American pharmaceutical research and development and Manufacturers Association Leaders from the Ministry of Commerce, the Ministry of health, the State Food and Drug Administration and the China Council for the promotion of international trade attended the meeting and delivered speeches More than 200 enterprise representatives and experts from the pharmaceutical industry of China and the United States also attended the meeting At the summit, experts from China and the United States delivered speeches or keynote reports on the protection of pharmaceutical intellectual property rights, pharmaceutical innovation and development, and public health rights and interests Chairman sang Guowei's speech was entitled "new drug research and development and intellectual property protection in China" At the summit, the organizers also specially arranged a round table dialogue on pharmaceutical intellectual property strategy of Chinese and American pharmaceutical enterprises, as well as a stage for speakers to interact with guests, so that participants can fully communicate Chairman sang met with Mr Chris weibach, chairman of the board of directors of the American pharmaceutical research and Manufacturers Association (PhRMA), vice chairman of the European Federation of pharmaceutical industry associations and CEO of Sanofi Aventis, who came to attend the summit, and expressed the hope that the cooperation between China and the United States in the pharmaceutical industry will continue to develop in a good and positive direction The summit also held a luncheon and dinner party, so that the guests could communicate in a relaxed atmosphere Jiang Zengwei, deputy secretary and Minister of the Party group of the Ministry of Commerce of the people's Republic of China, and Wang Xiaomin, Minister and deputy head of the U.S Embassy in China attended the luncheon and delivered speeches Song Ruilin, executive chairman of China Council for the promotion of drugs, presided over the luncheon, Wang Xiaomin, Minister and deputy head of the U.S Embassy in China, delivered a speech at the luncheon Jiang Zengwei, deputy secretary of the Party group and vice minister of the Ministry of Commerce of the people's Republic of China, delivered a speech at the luncheon Since 2009, the China US pharmaceutical industry summit has been held twice In 2009, the first China US pharmaceutical industry summit jointly held by China Council for the promotion of drugs and the American pharmaceutical research and development and manufacturers association was held in Changsha, China In 2010, the two associations signed a long-term cooperation framework agreement at the second China US pharmaceutical industry summit in Washington, D.C., and decided to hold a summit every year thereafter So far, the two sides have held three summits on issues related to intellectual property protection, incentives for innovation, measures to ensure the safety and effectiveness of drugs, and opportunities and challenges faced by global synchronous research and development of new drugs The summit has become an important exchange platform for the pharmaceutical industry between China and the United States Industry representatives hereby exchange views on public policy issues and strategies to promote the development of R & D-oriented pharmaceutical industry in China and the United States More than 30 domestic and foreign media, including Xinhua news agency, people's daily, Bloomberg news, associated press, AFP, Reuters and other mainstream media also sent reporters to attend the meeting The meeting was held with the support of the American Chamber of Commerce, China Council for the promotion of international trade and Shanghai Fosun Pharmaceutical Co., Ltd Brief introduction of China Pharmaceutical Industry Research and Development Association Founded in, it has gathered the backbone of domestic pharmaceutical research fields, such as China's top scientific research institutes, pharmaceutical universities and famous university pharmaceutical schools, as well as domestic representative innovative pharmaceutical enterprises and some clinical medical institutions; its member units represent the R & D capacity of China's pharmaceutical industry China Association for the promotion of drugs is a social group which takes research and development as the core, innovation as the purpose, clinical needs as the guidance, and production, learning and research closely combined to promote the development of medical research About the American pharmaceutical research and Manufacturers Association (Pharma), a leading pharmaceutical and biotechnology company in the United States, is committed to extending patient life and improving people's health through drug innovation Pharma's mission is to effectively promote and influence public policy so that it can encourage pharmaceutical and biotech companies to develop important new drugs Pharma member companies are the world's leaders in the development of new therapies: in 2010, member companies invested about 49.4 billion US dollars in the development of new drugs In China, Pharma works closely with the pharmaceutical research and development industry committee (rdpac) under the China Association of foreign funded enterprises, both of which have basically the same membership units and are R & D-oriented foreign pharmaceutical enterprises.